TP53 and ovarian carcinoma: Given the preclinical evidence suggesting WEE1i may be of most benefit in p53-mutated cancers, AZD1775 was assessed in combination with carboplatin and paclitaxcel for the treatment of p53-mutated, platinum-sensitive ovarian cancer.